Literature DB >> 17188135

Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival.

Babak Givi1, Suellen J Pommier, Alivia K Thompson, Brian S Diggs, Rodney F Pommier.   

Abstract

BACKGROUND: It is unclear whether there is a benefit to resection of primary gastrointestinal carcinoid neoplasm with hepatic metastases. We investigated whether primary tumor resection in this setting led to a significant difference in outcomes.
METHODS: A retrospective review of patients with abdominal carcinoid neoplasms between 1995 and 2006 was performed. Data collected on patients with proven carcinoid liver metastases at initial diagnosis included whether the primary neoplasm was resected, time to progression of liver metastases, and status at last follow-up. Progression-free survival and survival were calculated by the method of Kaplan-Meier and compared by the log-rank test.
RESULTS: There were 84 patients, 60 of whom had their primary neoplasm resected. The resected group had a greater median progression-free survival of 56 months, compared with 25 months for the primary nonresected group (P < .001). Median survival time for the resected group was longer at 159 months, compared with 47 months for the nonresected group (P < .001).
CONCLUSIONS: Resection of the primary neoplasm is associated with better progression-free survival and overall survival in patients with abdominal carcinoid neoplasms. Therefore, localization and resection of the primary neoplasm should be considered, even among patients in whom the primary neoplasm is asymptomatic.

Entities:  

Mesh:

Year:  2006        PMID: 17188135     DOI: 10.1016/j.surg.2006.07.033

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  57 in total

1.  Limitations of somatostatin scintigraphy in primary small bowel neuroendocrine tumors.

Authors:  Jessica E Maxwell; Scott K Sherman; Yusuf Menda; Donghong Wang; Thomas M O'Dorisio; James R Howe
Journal:  J Surg Res       Date:  2014-05-21       Impact factor: 2.192

2.  Pancreastatin predicts survival in neuroendocrine tumors.

Authors:  Scott K Sherman; Jessica E Maxwell; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe
Journal:  Ann Surg Oncol       Date:  2014-04-22       Impact factor: 5.344

3.  A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors.

Authors:  Jessica E Maxwell; Scott K Sherman; Kristen M Stashek; Thomas M O'Dorisio; Andrew M Bellizzi; James R Howe
Journal:  Surgery       Date:  2014-11-11       Impact factor: 3.982

4.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

Authors:  L Bodei; J Mueller-Brand; R P Baum; M E Pavel; D Hörsch; M S O'Dorisio; T M O'Dorisio; T M O'Dorisiol; J R Howe; M Cremonesi; D J Kwekkeboom; John J Zaknun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05       Impact factor: 9.236

5.  Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.

Authors:  Kendall J Keck; Allen Choi; Jessica E Maxwell; Guiying Li; Thomas M O'Dorisio; Patrick Breheny; Andrew M Bellizzi; James R Howe
Journal:  Ann Surg Oncol       Date:  2017-05-30       Impact factor: 5.344

6.  Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors?

Authors:  Allen B Choi; Jessica E Maxwell; Kendall J Keck; Andrew J Bellizzi; Joseph S Dillon; Thomas M OʼDorisio; James R Howe
Journal:  Pancreas       Date:  2017-10       Impact factor: 3.327

Review 7.  Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract.

Authors:  Peter E Goretzki; Martina T Mogl; Aycan Akca; Johann Pratschke
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

Review 8.  Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Jessica E Maxwell; Thomas M O'Dorisio; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2015-10-31       Impact factor: 3.495

Review 9.  [Indications and operative procedures for neuroendocrine liver metastases].

Authors:  T J Musholt; H Lang
Journal:  Chirurg       Date:  2009-02       Impact factor: 0.955

10.  Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling.

Authors:  Jennifer C Carr; Erin A Boese; Philip M Spanheimer; Fadi S Dahdaleh; Molly Martin; Daniel Calva; Blanca Schafer; David M Thole; Terry Braun; Thomas M O'Dorisio; M Sue O'Dorisio; James R Howe
Journal:  Surgery       Date:  2012-12       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.